Orally disintegrating dosage forms and taste-masking technologies; 2010

Expert Opinion on Drug Delivery

Volumn 8, Issue 5, 2011, Pages 665-675

  Douroumis, Dennis ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

complexation; drug delivery; microencapsulation; orally disintegrating tablets; taste masking

Indexed keywords

ALPRAZOLAM; CARBIDOPA PLUS LEVODOPA; CHLORASEPTIC; CLOZAPINE; DESLORATADINE; DIPHENHYDRAMINE; FAZALCO; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; HYOSCYAMINE; IBUPROFEN; LOPERAMIDE; LORATADINE; MIRTAZAPINE; NICOTINE; NUROFENTABS; OLANZAPINE; ONDANSETRON; OXYNORMORO; PARACETAMOL; PARALYOC; PHLOROGLUCINOL; PIROXICAM; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISOLONE SODIUM PHOSPHATE; RISPERIDONE; RIZATRIPTAN; SPASFON; TRIAMINIC; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ABDOMINAL PAIN; ALLERGY; ANXIETY DISORDER; ARTHRITIS; ASTHMA; COUGHING; DEPRESSION; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; FILM; FREEZE DRYING; HEAT; HUMAN; IRRITABLE COLON; MIGRAINE; NAUSEA AND VOMITING; ORALLY DISINTEGRATING DOSAGE; PAIN; PARKINSON DISEASE; PSYCHOSIS; QUICK DISSOLVING THIN FILM; REVIEW; SCHIZOPHRENIA; SORE THROAT; TABLET FORMULATION; TABLET PROPERTY; TASTE; TOBACCO DEPENDENCE;

ADMINISTRATION, ORAL; DRUG COMPOUNDING; FREEZE DRYING; HUMANS; TABLETS; TASTE; TASTE PERCEPTION;

EID: 79955123460     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.566553     Document Type: Review

References (70)

1. EMEA, Committee for Medicinal Products for Human Use (CHMP), Reflection Paper: Formulations of Choice for the Paediatric Population, Adoption by CHMP Sept. 21, 2006. Available from: www.emea.europa.eu/pdfs/human/paediatrics/ 19481005en.pdf [Accessed 20 August 2009]
2. FDA, Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, Dec. 2008). Available from: www.fda. gov/OHRMS/DOCKETS/98fr/FDA-2007-D-0365- gdl.pdf [Accessed 20 August 2009]
3. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS Pharm Sci Tech 2007;8:E1-7
4. Goel H, Vora N, Rana V. A novel approach to optimize and formulate fast disintegrating tablets for nausea and vomiting. AAPS Pharm Sci Tech 2008;9:774-81
5. Douroumis DD, Gryczke A, Schminke S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. AAPS Pharm Sci Tech 23 Dec 2010 [Epub ahead of print] DOI: 10.1208/s12249-010-9569-7
6. Zheng JY, Keeney MP. Taste masking analysis in pharmaceutical formulation development using an electronic tongue. Int J Pharm 2006;310:118-24 (Pubitemid 43287974)
7. Li L, Naini V, Ahmed SU. Utilization of a modified special-cubic design and an electronic tongue for bitterness masking formulation optimization. J Pharm Sci 2007;96:2723-34 (Pubitemid 47597821)
8. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin Drug Deliv 2007;4:417-26 (Pubitemid 47249139)
9. Ghosh TK, Pfister WR. Drug delivery to the oral cavity: molecules to market. Taylor & Francis Group, LLC; Boca Raton 2005
10. Orellana IG. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005;2:419-33
11. Pather SI, Rathbone MJ, S enel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008;5:531-42 (Pubitemid 351877432)
12. Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul 2009;3:26-39
13. Jeong SH, Lee J, Woo JS. Fast disintegrating tablets in oral controlled release formulation design and drug delivery: theory to practice. Wiley; New Jersey 2010
14. R.P Scherer Corp. Method for making freeze dried drug dosage forms. US5631023; 1997
15. R.P Scherer Corp. Process for preparing solid pharmaceutical dosage forms. US5738875; 1998
16. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82 (Pubitemid 28197414)
17. Poston KL, Waters C. Zydis selegiline in the management of Parkinsons disease. Expert Opin Pharmacother 2007;8:2615-24 (Pubitemid 350031298)
18. Hori H, Ueda N, Yoshimura R, et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009;10:741-5
19. Janssen Pharmaceutica, Inc. Pharmaceutical and other dosage forms. US5648093; 1997
20. Lafon. Galenic form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion. US4616047; 1986
21. Cima Labs, Inc. Effervescent dosage form with microparticles. US5178878; 1993
22. Cima Labs, Inc. Rapidly dissolving robust dosage form. US6024981; 2000
23. Cima Labs, Inc. Pediatric effervescent dosage form. US5223264; 1993
24. Cima Labs, Inc. Taste masking microparticles for oral dosage forms. US5607697; 1997
25. Cima Labs, Inc. Rapidly dissolving robust dosage form. US6024981; 2000
26. Cima Labs, Inc. Taste masking rapid release system. US6740341; 2004
27. Ethypharm , Inc. Process for manufacturing coated granules with masked taste and immediate release of the active principle. US6660382; 2003
28. Ethypharm, Inc. Particles with granulated crystalline Ibuprofen. US6951657; 2005
29. GattefosseTS SA. Tablet for crunching with masked taste and instant release of active principle and method for making same. WO0024385; 2000
30. Gattefosse ETS SA. Method for coating solid particles with a thermofusible agent and resulting coated solid particles. WO0207706; 2002
31. Gattefosse ETS SA. Method for preparing a pharmaceutical composition with modified release of the active principle comprising a matrix. WO9814176; 2000
32. Eurand America, Inc. Effervescent microcapsules. Effervescent microcapsules. US5639475; 1997
33. Eurand America, Inc. Effervescent microcapsules 5,709,886 ; 1998
34. Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture. US6139865; 2000
35. Eurand Pharmaceuticals Ltd. Taste masked pharmaceutical compositions prepared by coacervation. WO2006055142; 2006
36. Kyowa Hakko Kogyo Co. Rotary type tableting machine with lubricant spraying means. US5700492; 1997
37. Kyowa Hakko Kogyo Co. Process for the production of tablets US6464737; 2002.
38. Fertin Pharma AS. Chewing gum release. WO0213781; 2002
39. Fertin Pharma AS. Stable medicated chewing gum comprising cyclodextrin inclusion complex. WO2009006898; 2009
40. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1-11 (Pubitemid 44937538)
41. Guo X, Chang RK, Hussain MA. Ion-exchange resins as drug delivery carriers. J Pharm Sci 2009;98:3886-902
42. McNeil Consumer Products Co. Chewable medicament tablet containing means for taste masking. US4851226; 1989
43. McNeil Consumer Products Co. Taste masking and sustained release coatings for pharmaceuticals. US5075114; 1991
44. Ellan Corp. Plc. Controlled release powder and process for its preparation. US4952402; 1990
45. Fuisz Technologies Ltd. Process and apparatus form making rapidly dissolving dosage units and product there from. US5622719; 1997
46. Fuisz Technologies Ltd. Fast-dissolving comestible units formed under highspeed/high-pressure conditions. US5869098; 1999
47. Fuisz Technologies Ltd. Dosage forms containing taste masked active agents. US6165512; 2000
48. Yamanouchi Pharmaceutical Co., Ltd. Quick release coating preparation. EP0559897; 1992
49. Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof. US6872405; 2005
50. Yamanouchi Pharmaceutical Co., Ltd. Tablets quickly disintegrating in the oral cavity and process for producing the same. US6589554; 2003
51. Crowley MM, Zhang F, Repka MA, et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm 2007;33:909-26 (Pubitemid 47463803)
52. Repka MA, Battu SK, Upadhye SB, et al. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm 2007;33:1043-57 (Pubitemid 350034836)
53. Repka MA, Majumdar S, Kumar Battu S, et al. Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv 208;5:1357-76
54. Repka MA, McGinity JW. Influence of Vitamin E TPGS on the properties of hydrophilic films produced by hot-melt extrusion. Int J Pharm 2002;202:63-70 (Pubitemid 30466230)
55. Roehm GmbH & Co. Melt extrusion of salts of active ingredients. US20040253314; 2004
56. Roehm GmbH & Co. Method for producing an immediately decomposing oral form of administration which release active ingredients. US20060051412A1; 2006
57. Pharma Polymers, 51st International, EUDRAGIT® Workshop; 14 - 16 March 2006; Degussa AG, Business Line Pharma Polymers, Darmstadt, Germany
58. Cerea M, Zheng W, Young CR, McGinity JW. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets. Int J Pharm 2004;279:127-39 (Pubitemid 38968648)
59. Fukuda M, Peppas NA, McGinity JW. Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release 2006;115:121-9 (Pubitemid 44537498)
60. Crowley MM, Fredersdorf A, Schroeder B, et al. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films. Eur J Pharm Sci 2004;22:409-18 (Pubitemid 38953899)
61. Repka MA, McGinity JW. Physical-mechanical, moisture absorption and bioadhesive properties of hydroxypropylcellulose hot-melt extruded films. Biomaterials 2000;21:1509-17 (Pubitemid 30259295)
62. Repka MA, Prodduturi S, Stodghill SP. Production and characterization of hot-melt extruded films containing clotrimazole. Drug Dev Ind Pharm 2003;29:757-65 (Pubitemid 36899882)
63. Danjo K, Higuchi F, Otsuka A. Release of lidocaine from polymer film dosage forms. Chem Pharm Bull (Tokyo) 1994;43:1759-63
64. Patient information, Chloraseptic relief stripes, cherry, Prestige Brands, International, 2003. Available from: http//www.chloraseptic.com [Last accessed 27 January 2006]
65. Zengen, Inc. Edible film for relief of cough or symproms associated with pharyngitis. WO2004045537A2; 2004
66. McNeil-PPC, Inc. Fast dissolving orally consumable films. US7491406; 2009
67. McNeil-PPC, Inc. Fast dissolving orally consumable films containing a taste masking agent. US7648712; 2010
68. Lavipharm Laboratories, Inc.compositions and methods for mucosal delivery. US20030068378A1; 2003
69. Lavipharm Laboratories, Inc. Intraoral delivery of nicotine for smoking cessation. US20070298090A1; 2007
70. Lavipharm Laboratories, Inc. Water soluble and palatable complexes. US7125564; 2006